Dirk Müller‐Wieland

13.7k total citations · 2 hit papers
284 papers, 7.4k citations indexed

About

Dirk Müller‐Wieland is a scholar working on Endocrinology, Diabetes and Metabolism, Surgery and Molecular Biology. According to data from OpenAlex, Dirk Müller‐Wieland has authored 284 papers receiving a total of 7.4k indexed citations (citations by other indexed papers that have themselves been cited), including 130 papers in Endocrinology, Diabetes and Metabolism, 89 papers in Surgery and 89 papers in Molecular Biology. Recurrent topics in Dirk Müller‐Wieland's work include Diabetes Treatment and Management (77 papers), Diabetes Management and Research (59 papers) and Lipoproteins and Cardiovascular Health (47 papers). Dirk Müller‐Wieland is often cited by papers focused on Diabetes Treatment and Management (77 papers), Diabetes Management and Research (59 papers) and Lipoproteins and Cardiovascular Health (47 papers). Dirk Müller‐Wieland collaborates with scholars based in Germany, United States and United Kingdom. Dirk Müller‐Wieland's co-authors include Wilhelm Krone, C. Ronald Kahn, Jörg Kotzka, Jens C. Brüning, Jennifer A. Gillette, Markus Schubert, Paul C. Orban, Rüdiger Klein, Deborah J. Burks and Dinesh Gautam and has published in prestigious journals such as Science, New England Journal of Medicine and Proceedings of the National Academy of Sciences.

In The Last Decade

Dirk Müller‐Wieland

254 papers receiving 7.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Role of Brain Insulin Receptor in Control of Body Weight and Reproduction

2000 1.7k citations Dirk Müller‐Wieland et al. profile →
Definition, Classification and Diagnosis of Diabetes Mellitus

2019 377 citations Dirk Müller‐Wieland, Ulrich Müller et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Dirk Müller‐Wieland Germany	38	2.5k	2.0k	1.9k	1.8k	1.1k	284	7.4k
Wilhelm Krone Germany	41	2.7k 1.1×	1.8k 0.9×	1.6k 0.9×	2.6k 1.5×	1.3k 1.2×	182	7.8k
Peter J. Voshol Netherlands	53	3.4k 1.4×	1.5k 0.8×	1.8k 0.9×	2.6k 1.5×	944 0.8×	114	8.4k
Davide Lauro Italy	50	2.5k 1.0×	1.9k 1.0×	1.5k 0.8×	1.9k 1.1×	408 0.4×	206	7.3k
John J. Nolan Ireland	41	2.3k 0.9×	3.1k 1.6×	1.2k 0.6×	2.2k 1.3×	859 0.8×	115	7.6k
Barbara C. Hansen United States	40	3.5k 1.4×	2.1k 1.1×	1.9k 1.0×	3.1k 1.8×	1.1k 0.9×	159	9.1k
Vincent Mooser Switzerland	50	2.0k 0.8×	1.4k 0.7×	1.5k 0.8×	3.0k 1.7×	1.3k 1.2×	170	10.2k
Sunder Mudaliar United States	51	3.4k 1.4×	4.1k 2.1×	2.0k 1.1×	2.4k 1.4×	893 0.8×	118	9.4k
Hitoshi Ando Japan	44	1.8k 0.7×	842 0.4×	1.1k 0.6×	1.7k 1.0×	917 0.8×	255	8.1k
Paolo Magni Italy	40	1.5k 0.6×	1.1k 0.6×	930 0.5×	1.6k 0.9×	670 0.6×	161	6.6k
Niels Jessen Denmark	53	3.8k 1.5×	2.1k 1.1×	1.7k 0.9×	4.2k 2.4×	506 0.4×	234	9.4k

Countries citing papers authored by Dirk Müller‐Wieland

Since Specialization

Citations

This map shows the geographic impact of Dirk Müller‐Wieland's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dirk Müller‐Wieland with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dirk Müller‐Wieland more than expected).

Fields of papers citing papers by Dirk Müller‐Wieland

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dirk Müller‐Wieland. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dirk Müller‐Wieland. The network helps show where Dirk Müller‐Wieland may publish in the future.

Co-authorship network of co-authors of Dirk Müller‐Wieland

This figure shows the co-authorship network connecting the top 25 collaborators of Dirk Müller‐Wieland. A scholar is included among the top collaborators of Dirk Müller‐Wieland based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dirk Müller‐Wieland. Dirk Müller‐Wieland is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Brandts, Julia & Dirk Müller‐Wieland. (2025). Debate: Lipid-lowering Therapies and Diabetes Development. Current Atherosclerosis Reports. 27(1). 24–24. 2 indexed citations

Niederau, Christoph, et al.. (2025). Definition, Klassifikation, Diagnostik und Differenzialdiagnostik des Diabetes mellitus: Update 2025. Diabetologie und Stoffwechsel. 20(S 02). S127–S143. 1 indexed citations

Aberle, Jens, et al.. (2025). Therapie des Typ-2-Diabetes. Diabetologie und Stoffwechsel. 20(S 02). S193–S210.

Seitz, Lisa, et al.. (2024). MSR162 Identification of Patients With Obesity, Based on Their Comorbidities. Value in Health. 27(12). S470–S470. 1 indexed citations

Marx, Nikolaus, Massimo Federici, Katharina Schütt, et al.. (2024). Linee guida ESC 2023 per il trattamento delle malattie cardiovascolari nei pazienti diabetici. Giornale italiano di cardiologia. 25(1). e1–e103. 2 indexed citations

Görgens, Sven W., et al.. (2024). Prevalence of obesity and cardiovascular disease in adults with type 2 diabetes and use of diabetes medication in Germany: A claims data study. Diabetes Obesity and Metabolism. 26(12). 5636–5645.

Marx, Nikolaus, Lars Rydén, Massimo Federici, et al.. (2024). Great debate: pre-diabetes is not an evidence-based treatment target for cardiovascular risk reduction. European Heart Journal. 45(48). 5117–5126. 4 indexed citations

Balfanz, Paul, Dirk Müller‐Wieland, Stephan Jonas, et al.. (2024). Monitoring individualized glucose levels predicts risk for bradycardia in type 2 diabetes patients with chronic kidney disease: a pilot study. Scientific Reports. 14(1). 30290–30290. 2 indexed citations

Schütt, Katharina, et al.. (2023). Influenza vaccination in patients affected by diabetes. European Heart Journal Supplements. 25(Supplement_A). A36–A41. 4 indexed citations

10.

Teufel, Andreas, Andreas Geier, Christoph Sarrazin, et al.. (2023). Intersektorales Management von Patienten mit unklarer Leberwerterhöhung und nichtalkoholischer Fettlebererkrankung (NAFLD). Zeitschrift für Gastroenterologie. 61(8). 1028–1036. 1 indexed citations

11.

Brandts, Julia, Sascha R. Tittel, Peter Bramlage, et al.. (2023). LDL- and non-HDL-cholesterol in type 1 and type 2 diabetes: Lipid goal attainment in a large German diabetes registry. Atherosclerosis. 379. S58–S58. 1 indexed citations

12.

Hartmann, Bojan, Paul Balfanz, Niels‐Ulrik Korbinian Hartmann, et al.. (2022). Glycaemic variability is associated with all-cause mortality in COVID-19 patients with ARDS, a retrospective subcohort study. Scientific Reports. 12(1). 9862–9862. 8 indexed citations

13.

Schloot, Nanette C., et al.. (2022). Age‐dependent prevalence of type 2 diabetes, cardiovascular risk profiles and use of diabetes drugs in Germany using health claims data. Diabetes Obesity and Metabolism. 25(3). 767–775. 4 indexed citations

14.

Bosy‐Westphal, Anja, Martina de Zwaan, Sarah Egert, et al.. (2019). Quantitative Empfehlung zur Zuckerzufuhr in Deutschland: Kurzfassung des Konsensuspapiers der Deutschen Adipositas-Gesellschaft e. V. (DAG), der Deutschen Diabetes Gesellschaft e. V. (DDG) und der Deutschen Gesellschaft für Ernährung e. V. (DGE). OpenAgrar. 5 indexed citations

15.

Ray, Kausik K., Lawrence A. Leiter, Dirk Müller‐Wieland, et al.. (2018). Alirocumab vs usual lipid‐lowering care as add‐on to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: The ODYSSEY DM‐DYSLIPIDEMIA randomized trial. Diabetes Obesity and Metabolism. 20(6). 1479–1489. 71 indexed citations

16.

Leiter, Lawrence A., Bertrand Cariou, Dirk Müller‐Wieland, et al.. (2017). Efficacy and safety of alirocumab in insulin‐treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: The ODYSSEY DM‐INSULIN randomized trial. Diabetes Obesity and Metabolism. 19(12). 1781–1792. 100 indexed citations

17.

Müller‐Wieland, Dirk, Birgit Knebel, Jutta Haas, & Jörg Kotzka. (2012). SREBP-1 und Fettleber. Herz. 37(3). 273–280. 10 indexed citations

18.

Ristow, Michael, Hindrik Mulder, Tim J. Schulz, et al.. (2003). Frataxin deficiency in pancreatic islets causes diabetes due to loss of β cell mass. Journal of Clinical Investigation. 112(4). 527–534. 107 indexed citations

19.

Al‐Hasani, Hadi, Norbert Tennagels, Waltraud Paßlack, et al.. (1997). Identification of Ser‐1275 and Ser‐1309 as autophosphorylation sites of the insulin receptor¹. FEBS Letters. 400(1). 65–70. 19 indexed citations

20.

Cox, Nancy J., et al.. (1988). Four RFLPS of the human insulin receptor gene: PstI, KpnI, RsaI (2 RFLPs). Nucleic Acids Research. 16(16). 8204–8204. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact